Sun Pharmaceutical Industries Share Price
Free Demat with Zero AMC*
+ Free 1st Year AMC
Summary
The stock has recorded a trading volume of 23,48,251 shares,. Its Average Traded Price (ATP) is ₹1853.32, while the Last Traded Quantity at the Last Traded Price (LTQ@LTP) is 111 @ ₹1860.00.
Sun Pharmaceutical Industries has an upper circuit limit of ₹2011.90 and a lower circuit limit of ₹1646.10. The total value traded stands at ₹435.21 CR, and the delivery percentage for the day is 62.07%.
The stock is currently traded with a market lot size of 1. Sun Pharmaceutical Industries also offers a dividend yield of 0.88%.
Sun Pharmaceutical Industries Share Price Chart
Sun Pharmaceutical Industries Share Key Metrics
Volume
23.48 L
Market Cap
446276.30 CR
LTQ@LTP
111@1860.00
ATP
1853.32
Var Margin
12.5 %
Circuit Range
1646.1-2011.9
Delivery %
62.07 %
Value
435.21 CR
ASM/GSM
No
Market Lot
1
Sun Pharmaceutical Industries Resistance and Support
Pivot 1810.37
Resistance
First Resistance
1858.34
Second Resistance
1887.67
Third Resistance
1935.64
Support
First Support
1781.04
Second Support
1733.07
Third Support
1703.74
Sun Pharmaceutical Industries Futures & Options
1860
31 (1.69%)
Sun Pharmaceutical Industries Option Chain
View Price, OI, Greeks & More...
23NOV26
1872.20
32.30 (1.76%)
29DEC26
1886.80
35.60 (1.92%)
25JAN27
1895.00
33.50 (1.80%)
SUNPHARMA|23NOV26 CE 1860.00
36.55
16.8 (85.06%)
SUNPHARMA|23NOV26 PE 1880.00
34.35
-19.15 (-35.79%)
Sun Pharmaceutical Industries Shareholding Pattern
View More- 2018-19
- 2019-20
- 2020-21
- 2021-22
- 2022-23
- 2023-24
- 2024-25
- 2025-26
- 2026-27
Total Promoters
Sun Pharmaceutical Industries Corporate Actions
| Date | Agenda |
|---|---|
| 2026-10-30 | Quarterly Results |
| 2026-07-31 | Quarterly Results |
| 2026-05-22 | Audited Results & Final Dividend |
| 2026-01-31 | Quarterly Results & Interim Dividend |
| 2025-11-05 | Quarterly Results |
| 2025-07-31 | Quarterly Results |
| 2025-05-22 | Audited Results & Final Dividend |
| 2025-01-31 | Quarterly Results & Interim Dividend |
| 2024-10-28 | Quarterly Results |
| 2026-10-12 | Others |
| Ex Date | Record Date | |
|---|---|---|
| 2026-07-07 | 2026-07-07 | View More |
Sun Pharmaceutical Industries News
Sun Pharmaceutical Industries Ltd - 524715 - Completion And Results Of Postal Ballot Dated 01 October 2026
Sun Pharmaceutical announced that shareholders have approved special resolutions via postal ballot. The approvals include the enhancement of borrowing and investment limits, along with the authorization to create security and encumbrance over shares.
Oct 31 2026 20:14:03
Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sun Pharma has received US FDA approval for ILUMYA to treat adults with active psoriatic arthritis. The approval expands the drug's use beyond plaque psoriasis and is supported by Phase 3 clinical studies.
Oct 30 2026 08:05:37
Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Allotment
Sun Pharmaceutical has completed the allotment of unsecured, redeemable non-convertible debentures (NCDs) worth Rs.7,816 crore on a private placement basis. The base issue of Rs.7,000 crore was fully subscribed, and a greenshoe option of Rs.816 crore was exercised.
Oct 26 2026 12:30:09
Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sun Pharma will present long-term follow-up data on UNLOXCYT for advanced cutaneous squamous cell carcinoma at the ESMO 2026 Congress. The data highlights a 34% complete response in locally advanced disease and consistent safety with low high-grade adverse events.
Oct 23 2026 18:01:34
Sun Pharmaceutical Industries Ltd - 524715 - Board Meeting Intimation for Consideration And Approval The Unaudited Financial Results For The Quarter And Half Year Ended 30 September 2026
Sun Pharmaceutical board is scheduled to meet on 30 October 2026 for financial results. The meeting will cover the quarter and half year ended 30 September 2026.
Oct 14 2026 20:16:45
Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Credit Rating
CRISIL and ICRA have assigned AAA/Stable ratings to Sun Pharma's proposed Rs.15,000 crore Non-Convertible Debentures. Both agencies reaffirmed the existing ratings on commercial paper and bank facilities. The ratings factor in the company's profile and the proposed Organon acquisition.
Oct 13 2026 17:53:34
Sun Pharmaceutical Industries Ltd - 524715 - Board Meeting Outcome for Outcome Of The Board Meeting Held On 12 October 2026
Sun Pharmaceutical's board approved the issuance of listed, unsecured, redeemable non-convertible debentures up to ₹10,000 crore on a private placement basis. Additionally, Gautam Doshi resigned as a Non-Executive, Independent Director effective October 12, 2026, due to personal reasons.
Oct 12 2026 19:56:53
Sun Pharmaceutical Industries Ltd - 524715 - Board Meeting Intimation for Consideration And Approval Of The Issuance Of Listed, Rated, Unsecured, Redeemable, Non-Convertible Debentures
Sun Pharmaceutical's board will meet on 12 October 2026 to consider issuing unsecured, redeemable non-convertible debentures up to Rs.15,000 crore. The issuance will be on a private placement basis in one or more tranches.
Oct 07 2026 20:39:10
Sun Pharmaceutical Industries Management
| Name | Position |
|---|---|
| Anoop Deshpande | Company Secretary & Compliance Officer |
| Dilip S Shanghvi | Chairman & Managing Director |
Sun Pharmaceutical Industries Similar Stocks
Divi's Laboratories Ltd.
10320.50
180.00 (1.78%)
Torrent Pharmaceuticals Ltd.
4750.00
40.00 (0.85%)
Laurus Labs Ltd.
2340.00
-6.00 (0.26%)
Apollo Hospitals Enterprise Ltd.
8446.00
75.00 (0.90%)
Lenskart Solutions Ltd.
724.75
6.40 (0.89%)
Zydus Lifesciences Ltd.
1197.90
4.90 (0.41%)
Dr. Reddy's Laboratories Ltd.
1373.00
7.00 (0.51%)
Cipla Ltd.
1411.00
6.90 (0.49%)
Mankind Pharma Ltd.
2540.00
22.00 (0.87%)
Aurobindo Pharma Ltd.
1800.00
15.00 (0.84%)
Sun Pharmaceutical Industries FAQs
Open Your Free
Demat Account Now!
AMC for First Year
Auto Square Off Charges
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools

Open Your Free
Demat Account Now!
AMC For First Year
Account Opening Fee
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools
Invest in SUNPHARMA
Account Opening Fee AMC for 1st Year Auto Square Off Charges Call & Trade
+ Free 1st Year AMC